CD274 and esophageal squamous cell carcinoma: In summary, from the Chinese healthcare system perspective, serplulimab plus chemotherapy might not be considered cost-effective in the first-line treatment for PD-L1-positive advanced ESCC patients despite the extension of PFS and OS.